Alnylam Pharmaceuticals ALNY Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| AMVUTTRA | $889.93M+7.7% | $826.59M+20.6% | $685.3M+39.3% | $491.95M+58.7% | $309.99M+8.2% | |
| GIVLAARI | $74.39M-14.3% | $86.8M+17.5% | $73.87M-8.6% | $80.85M+20.7% | $66.97M+3.6% | |
| ONPATTRO | $20.48M-35.4% | $31.69M-18.9% | $39.08M-25.6% | $52.54M+6.2% | $49.49M-11.8% | |
| OXLUMO | $51.32M+3.4% | $49.65M-6.0% | $52.83M+12.7% | $46.87M+11.4% | $42.09M-3.4% | |
| Transaction price by Product | ||||||
| License | $1.74B0.0% | $1.74B0.0% | $1.74B— | —— | —— | |
| Research Services Obligation | $100.5M0.0% | $100.5M0.0% | $100.5M0.0% | $100.5M— | —— | |
| Roche Development Services Obligation | $1.06B0.0% | $1.06B— | —— | $1.06B+13.2% | $937.53M0.0% | |
| Roche License Obligation | $675M0.0% | $675M— | —— | $675M+80.0% | $375M0.0% | |
| Roche Technology Transfer Obligation | $2M0.0% | $2M— | —— | $2M0.0% | $2M0.0% | |
| Maximum funding by Product | ||||||
| ALN-AGT Phase 2 Clinical Trial | $26M0.0% | $26M— | —— | —— | —— | |
| ALN-AGT Phase 3 Clinical Trial | $12M+100% | $6M-66.7% | $18M— | —— | —— | |
| HELIOS-B Phase 3 Clinical Trial | $70M0.0% | $70M— | —— | —— | —— | |
| Effective interest rate (as percent) by Product | ||||||
| Vutrisiran | 49%+3.0pp | 46%— | —— | —— | —— | |
| Zilebesrian | 32%0.0pp | 32%— | —— | —— | —— | |
| Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements by Product | ||||||
| Vutrisiran | $30.14M+55.2% | $19.43M0.0% | $19.43M0.0% | $19.43M0.0% | $19.43M— | |
| Zilebesrian | $5.28M0.0% | $5.28M0.0% | $5.28M0.0% | $5.28M0.0% | $5.28M— | |
| Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value by Product | ||||||
| Vutrisiran | $187.94M-3.2% | $194.15M— | —— | —— | —— | |
| Zilebesrian | $19.61M+15.1% | $17.05M— | —— | —— | —— | |
| Interest Expense by Product | ||||||
| Vutrisiran | $23.93M+17.1% | $20.43M0.0% | $20.43M0.0% | $20.43M0.0% | $20.43M— | |
| Zilebesrian | $1.85M+7.8% | $1.71M0.0% | $1.71M0.0% | $1.71M0.0% | $1.71M— | |
| Liabilities related to the sale of future royalties and development funding by Product | ||||||
| Vutrisiran | $98.5M+4.2% | $94.5M— | —— | —— | —— | |
| Zilebesrian | $7.5M+10.3% | $6.8M— | —— | —— | —— | |
| Liabilities related to the sale of future royalties and development funding, net of current portion by Product | ||||||
| Vutrisiran | $89.4M-10.3% | $99.7M— | —— | —— | —— | |
| Zilebesrian | $12.1M+17.5% | $10.3M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Alnylam Pharmaceuticals break its business down?
- Alnylam Pharmaceuticals (ALNY) reports total revenues by product across 4 parts — AMVUTTRA, GIVLAARI, ONPATTRO and OXLUMO. Each is extracted from the segment footnotes and tracked over time.
- Where does Alnylam Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Alnylam Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
